Canada’s national nuclear laboratory and leading particle accelerator centre partner to host global forum on targeted radiopharmaceutical therapy
CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan 30 (Bernama-GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, and TRIUMF, one of the world’s leading particle accelerator centres, jointly announced today that they are partnering to co-host the 11th Targeted-Alpha-Therapy Symposium (TAT11) to be held from April 1 – 5, 2019 at the Fairmont Château Laurier in Ottawa.
TAT11 is a global forum for academic and industry leaders to meet and discuss the latest technical, regulatory and clinical developments in targeted radiopharmaceutical therapy. The potential benefits of targeted-alpha-therapy in the battle against cancer and other diseases are significant. While existing radiation treatments target all cells in the vicinity of a tumor, both healthy and cancerous, targeted-alpha-therapy focuses the treatment application to cancerous or unhealthy cells. This limits the overall radiation dose a patient may receive, holds promise of better patient outcomes, and encourages a faster recovery time following treatment.
CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan 30 (Bernama-GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, and TRIUMF, one of the world’s leading particle accelerator centres, jointly announced today that they are partnering to co-host the 11th Targeted-Alpha-Therapy Symposium (TAT11) to be held from April 1 – 5, 2019 at the Fairmont Château Laurier in Ottawa.
TAT11 is a global forum for academic and industry leaders to meet and discuss the latest technical, regulatory and clinical developments in targeted radiopharmaceutical therapy. The potential benefits of targeted-alpha-therapy in the battle against cancer and other diseases are significant. While existing radiation treatments target all cells in the vicinity of a tumor, both healthy and cancerous, targeted-alpha-therapy focuses the treatment application to cancerous or unhealthy cells. This limits the overall radiation dose a patient may receive, holds promise of better patient outcomes, and encourages a faster recovery time following treatment.
No comments:
Post a Comment